Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff.  The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 257.23 Danish Krone on Monday morning after trials of its new obesity shot, [...]